logo-loader
viewScancell Holdings PLC

Full interview: Scancell back in the clinic with a phase II trial of its flagship skin cancer treatment

Scancell Holdings PLC's (LON:SCLP) Cliff Holloway tells Proactive London's Andrew Scott they've begun the UK arm of the phase II trial of its flagship skin cancer treatment.

The trial is testing the safety and efficacy of SCIB1 in metastatic melanoma patients who are also receiving Merck’s checkpoint inhibitor Keytruda.

Quick facts: Scancell Holdings PLC

Price: 6.45 GBX

LSE:SCLP
Market: LSE
Market Cap: £30.02 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: Scancell receives US approval for its SCIB1 skin cancer...

Headlines from the Proactive UK newsroom. Scancell (LON:SCLP) has received IND approval from the US FDA for its SCIB1 skin cancer treatment. the company will now start a US Phase 2 trial in combination with leading drug Keytruda to see if it reduces toxicity compared to other...

3 weeks ago

2 min read